Alessandro Granito Selected Research

Hepatocellular Carcinoma (Hepatoma)

12/2021	Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders.
7/2021	Real-Life Clinical Data of Cabozantinib for Unresectable Hepatocellular Carcinoma.
1/2021	Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience.
1/2021	Correction to: Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib.
1/2021	Experience with regorafenib in the treatment of hepatocellular carcinoma.
1/2021	Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC.
1/2021	Comparison of Prognostic Scores in Patients With Hepatocellular Carcinoma Treated With Sorafenib.
12/2020	Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.
12/2020	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma.
1/2020	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Alessandro Granito Research Topics

Disease

28	Hepatocellular Carcinoma (Hepatoma) 12/2021 - 01/2013
10	Autoimmune Hepatitis 01/2021 - 12/2002
9	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 03/2021 - 10/2002
8	Liver Diseases (Liver Disease) 06/2021 - 10/2002
7	Celiac Disease (Celiac Sprue) 01/2022 - 10/2002
6	Neoplasms (Cancer) 06/2021 - 01/2015
5	Fatigue 07/2021 - 02/2015
5	Fibrosis (Cirrhosis) 01/2018 - 06/2009
4	Disease Progression 01/2022 - 06/2009
4	Hepatitis 01/2021 - 12/2005
4	Infections 01/2021 - 06/2005
4	Hepatitis C 06/2009 - 02/2005
3	Liver Failure 01/2022 - 06/2009
3	Liver Neoplasms (Liver Cancer) 01/2021 - 03/2015
3	COVID-19 01/2021 - 01/2021
3	Chronic Hepatitis C 06/2009 - 06/2005
2	Hemorrhage 12/2021 - 01/2013
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2017 - 09/2008
2	Hypertension (High Blood Pressure) 01/2017 - 03/2016
2	Sclerosing Cholangitis 11/2010 - 10/2002
2	Chronic Hepatitis (Chronic Active Hepatitis) 12/2005 - 02/2005
1	Non-alcoholic Fatty Liver Disease 06/2022
1	Ascites 01/2022
1	Esophageal and Gastric Varices (Esophageal Varices) 12/2021
1	Autoimmune Diseases (Autoimmune Disease) 04/2021
1	Immune System Diseases (Immune Disorders) 03/2021
1	Rheumatoid Arthritis 01/2021
1	Rheumatic Diseases (Rheumatism) 01/2021
1	Pneumonia (Pneumonitis) 01/2021
1	Metabolic Bone Diseases (Osteopenia) 12/2018
1	Osteoporosis 12/2018
1	Thrombosis (Thrombus) 02/2018
1	Hand-Foot Syndrome 06/2015
1	Neoplasm Metastasis (Metastasis) 03/2015
1	Pruritus (Itching) 02/2015
1	Connective Tissue Diseases (Connective Tissue Disease) 03/2014
1	IgA Deficiency 03/2010
1	Neuroblastoma 01/2010
1	Hearing Loss (Hearing Impairment) 08/2009

Drug/Important Bio-Agent (IBA)

22	Sorafenib (BAY 43-9006)FDA Link 12/2021 - 01/2013
20	AntibodiesIBA 05/2021 - 10/2002
13	AutoantibodiesIBA 03/2021 - 02/2005
5	Immunoglobulin G (IgG)IBA 01/2021 - 07/2007
5	regorafenibIBA 01/2021 - 01/2017
4	Antinuclear AntibodiesIBA 03/2021 - 01/2010
4	Antiviral Agents (Antivirals)IBA 01/2021 - 02/2005
4	GliadinIBA 03/2010 - 10/2002
3	BilirubinIBA 01/2022 - 06/2015
3	Transaminases (Aminotransferases)IBA 07/2021 - 06/2009
3	Pharmaceutical PreparationsIBA 01/2021 - 06/2015
3	Capecitabine (Xeloda)FDA Link 02/2018 - 01/2013
3	Immunoglobulin A (IgA)IBA 03/2010 - 10/2002
3	Protein Glutamine gamma Glutamyltransferase 2IBA 06/2008 - 10/2002
2	Glutens (Glutelin)IBA 01/2022 - 10/2002
2	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 04/2021 - 02/2008
2	Tyrosine Kinase InhibitorsIBA 01/2021 - 03/2016
2	GadoliniumIBA 01/2018 - 10/2015
2	gadolinium ethoxybenzyl DTPA FDA Link 01/2018 - 10/2015
2	Ethanol (Ethyl Alcohol)IBA 01/2017 - 09/2008
2	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 02/2015 - 02/2008
2	Mycophenolic Acid (Cellcept)FDA LinkGeneric 11/2010 - 06/2009
2	Cyclosporine (Ciclosporin)FDA LinkGeneric 11/2010 - 06/2009
2	Budesonide (Pulmicort)FDA LinkGeneric 11/2010 - 06/2009
2	Peptides (Polypeptides)IBA 03/2010 - 06/2008
2	AutoantigensIBA 01/2010 - 06/2005
2	SteroidsIBA 06/2009 - 02/2008
2	Immunoglobulins (Immunoglobulin)IBA 07/2007 - 05/2006
2	EpitopesIBA 05/2006 - 06/2005
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2021
1	cabozantinibIBA 07/2021
1	GangliosidesIBA 05/2021
1	Proteins (Proteins, Gene)FDA Link 03/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	anti-dsDNA autoantibodyIBA 01/2021
1	AlbuminsIBA 01/2021
1	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2021
1	Interleukin-6 (Interleukin 6)IBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	tocilizumab (atlizumab)FDA Link 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Pentetic Acid (DTPA)FDA LinkGeneric 01/2018
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2017
1	Contrast MediaIBA 10/2015
1	gadobenic acid (gadobenate dimeglumine)FDA Link 10/2015
1	Yttrium-90IBA 03/2015
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 02/2015
1	Proto-Oncogene Proteins c-metIBA 01/2015
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2015
1	factor AIBA 01/2015
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2015
1	liver antigen LA-1IBA 11/2010
1	Tacrolimus (Prograf)FDA LinkGeneric 06/2009

Therapy/Procedure

16	Therapeutics 01/2022 - 02/2005
2	Liver Transplantation 01/2017 - 11/2010
1	Mediterranean Diet 06/2022
1	Immunotherapy 06/2021
1	Gluten-Free Diet 12/2018
1	Radiofrequency Ablation 01/2017
1	Drug Therapy (Chemotherapy) 03/2015
1	Retreatment 01/2014